A novel treatment strategy using indocyanine green for transarterial chemoembolization in BCLC stage C hepatocellular carcinoma

Jie Mei, Shao Hua Li, Qiao Xuan Wang, Xiao Ping Zhong, Liang He Lu, Anna Kan, Wei Wei, Rong Ping Guo

Research output: Contribution to journalArticle

Abstract

Purpose: The aim of our study was to propose a strategy based on indocyanine green (ICG) (SBI) to provide better clinical guidelines for transarterial chemoembolization (TACE) treatments for Barcelona clinic liver cancer (BCLC) stage C hepatocellular carcinoma (HCC) patients. Materials and Methods: From October 2005 to December 2012, 112 BCLC stage C HCC patients initially treated with TACE were investigated, randomly divided into a training cohort (n = 79) and validation cohort (n = 33). In training group, the patients were grouped based on their 15 minutes ICG retention rate (ICG R15), different chemo drugs and dose of lipidol in TACE. Overall survival (OS) and progression-free survival (PFS) were analyzed in subgroups. Strategy based on ICG was built and verified in validation group. Results: For those patients with ICG R15 values >10%, the lipiodol ≤10 mL group showed better survival than the lipiodol >10 mL group. For those patients with ICG R15 values ≤10%, the group that received triple-drug chemotherapy treatments with lipiodol diameter ratio values between 1 and 3 showed better survival than the other group. Patients who conformed with the SBI had better survival times than those who did not conform with the SBI, in both the training cohort (median OS 10.3 vs 5.1 months; P <.001; median PFS, 3.3 vs 2.1 months; P =.006) and the validation cohort (median OS 8.9 vs 7.1 months; P =.087; median PFS, 6.6 vs 2.3 months; P <.001). Conclusions: The SBI is suitable and may provide survival benefits for TACE treatments in BCLC stage C HCC patients.

Original languageEnglish (US)
Pages (from-to)62-76
Number of pages15
JournalCancer medicine
Volume9
Issue number1
DOIs
StatePublished - Jan 1 2020

Fingerprint

Indocyanine Green
Liver Neoplasms
Hepatocellular Carcinoma
Survival
Ethiodized Oil
Disease-Free Survival
Therapeutics
Pharmaceutical Preparations
Guidelines
Drug Therapy

Keywords

  • BCLC stage C
  • hepatocellular carcinoma
  • indocyanine green
  • transarterial chemoembolization
  • treatment strategy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

A novel treatment strategy using indocyanine green for transarterial chemoembolization in BCLC stage C hepatocellular carcinoma. / Mei, Jie; Li, Shao Hua; Wang, Qiao Xuan; Zhong, Xiao Ping; Lu, Liang He; Kan, Anna; Wei, Wei; Guo, Rong Ping.

In: Cancer medicine, Vol. 9, No. 1, 01.01.2020, p. 62-76.

Research output: Contribution to journalArticle

Mei, Jie ; Li, Shao Hua ; Wang, Qiao Xuan ; Zhong, Xiao Ping ; Lu, Liang He ; Kan, Anna ; Wei, Wei ; Guo, Rong Ping. / A novel treatment strategy using indocyanine green for transarterial chemoembolization in BCLC stage C hepatocellular carcinoma. In: Cancer medicine. 2020 ; Vol. 9, No. 1. pp. 62-76.
@article{4d92dcb5eafc4ad2baa9e8962a529c0e,
title = "A novel treatment strategy using indocyanine green for transarterial chemoembolization in BCLC stage C hepatocellular carcinoma",
abstract = "Purpose: The aim of our study was to propose a strategy based on indocyanine green (ICG) (SBI) to provide better clinical guidelines for transarterial chemoembolization (TACE) treatments for Barcelona clinic liver cancer (BCLC) stage C hepatocellular carcinoma (HCC) patients. Materials and Methods: From October 2005 to December 2012, 112 BCLC stage C HCC patients initially treated with TACE were investigated, randomly divided into a training cohort (n = 79) and validation cohort (n = 33). In training group, the patients were grouped based on their 15 minutes ICG retention rate (ICG R15), different chemo drugs and dose of lipidol in TACE. Overall survival (OS) and progression-free survival (PFS) were analyzed in subgroups. Strategy based on ICG was built and verified in validation group. Results: For those patients with ICG R15 values >10{\%}, the lipiodol ≤10 mL group showed better survival than the lipiodol >10 mL group. For those patients with ICG R15 values ≤10{\%}, the group that received triple-drug chemotherapy treatments with lipiodol diameter ratio values between 1 and 3 showed better survival than the other group. Patients who conformed with the SBI had better survival times than those who did not conform with the SBI, in both the training cohort (median OS 10.3 vs 5.1 months; P <.001; median PFS, 3.3 vs 2.1 months; P =.006) and the validation cohort (median OS 8.9 vs 7.1 months; P =.087; median PFS, 6.6 vs 2.3 months; P <.001). Conclusions: The SBI is suitable and may provide survival benefits for TACE treatments in BCLC stage C HCC patients.",
keywords = "BCLC stage C, hepatocellular carcinoma, indocyanine green, transarterial chemoembolization, treatment strategy",
author = "Jie Mei and Li, {Shao Hua} and Wang, {Qiao Xuan} and Zhong, {Xiao Ping} and Lu, {Liang He} and Anna Kan and Wei Wei and Guo, {Rong Ping}",
year = "2020",
month = "1",
day = "1",
doi = "10.1002/cam4.2671",
language = "English (US)",
volume = "9",
pages = "62--76",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - A novel treatment strategy using indocyanine green for transarterial chemoembolization in BCLC stage C hepatocellular carcinoma

AU - Mei, Jie

AU - Li, Shao Hua

AU - Wang, Qiao Xuan

AU - Zhong, Xiao Ping

AU - Lu, Liang He

AU - Kan, Anna

AU - Wei, Wei

AU - Guo, Rong Ping

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Purpose: The aim of our study was to propose a strategy based on indocyanine green (ICG) (SBI) to provide better clinical guidelines for transarterial chemoembolization (TACE) treatments for Barcelona clinic liver cancer (BCLC) stage C hepatocellular carcinoma (HCC) patients. Materials and Methods: From October 2005 to December 2012, 112 BCLC stage C HCC patients initially treated with TACE were investigated, randomly divided into a training cohort (n = 79) and validation cohort (n = 33). In training group, the patients were grouped based on their 15 minutes ICG retention rate (ICG R15), different chemo drugs and dose of lipidol in TACE. Overall survival (OS) and progression-free survival (PFS) were analyzed in subgroups. Strategy based on ICG was built and verified in validation group. Results: For those patients with ICG R15 values >10%, the lipiodol ≤10 mL group showed better survival than the lipiodol >10 mL group. For those patients with ICG R15 values ≤10%, the group that received triple-drug chemotherapy treatments with lipiodol diameter ratio values between 1 and 3 showed better survival than the other group. Patients who conformed with the SBI had better survival times than those who did not conform with the SBI, in both the training cohort (median OS 10.3 vs 5.1 months; P <.001; median PFS, 3.3 vs 2.1 months; P =.006) and the validation cohort (median OS 8.9 vs 7.1 months; P =.087; median PFS, 6.6 vs 2.3 months; P <.001). Conclusions: The SBI is suitable and may provide survival benefits for TACE treatments in BCLC stage C HCC patients.

AB - Purpose: The aim of our study was to propose a strategy based on indocyanine green (ICG) (SBI) to provide better clinical guidelines for transarterial chemoembolization (TACE) treatments for Barcelona clinic liver cancer (BCLC) stage C hepatocellular carcinoma (HCC) patients. Materials and Methods: From October 2005 to December 2012, 112 BCLC stage C HCC patients initially treated with TACE were investigated, randomly divided into a training cohort (n = 79) and validation cohort (n = 33). In training group, the patients were grouped based on their 15 minutes ICG retention rate (ICG R15), different chemo drugs and dose of lipidol in TACE. Overall survival (OS) and progression-free survival (PFS) were analyzed in subgroups. Strategy based on ICG was built and verified in validation group. Results: For those patients with ICG R15 values >10%, the lipiodol ≤10 mL group showed better survival than the lipiodol >10 mL group. For those patients with ICG R15 values ≤10%, the group that received triple-drug chemotherapy treatments with lipiodol diameter ratio values between 1 and 3 showed better survival than the other group. Patients who conformed with the SBI had better survival times than those who did not conform with the SBI, in both the training cohort (median OS 10.3 vs 5.1 months; P <.001; median PFS, 3.3 vs 2.1 months; P =.006) and the validation cohort (median OS 8.9 vs 7.1 months; P =.087; median PFS, 6.6 vs 2.3 months; P <.001). Conclusions: The SBI is suitable and may provide survival benefits for TACE treatments in BCLC stage C HCC patients.

KW - BCLC stage C

KW - hepatocellular carcinoma

KW - indocyanine green

KW - transarterial chemoembolization

KW - treatment strategy

UR - http://www.scopus.com/inward/record.url?scp=85074892564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074892564&partnerID=8YFLogxK

U2 - 10.1002/cam4.2671

DO - 10.1002/cam4.2671

M3 - Article

C2 - 31701652

AN - SCOPUS:85074892564

VL - 9

SP - 62

EP - 76

JO - Cancer Medicine

JF - Cancer Medicine

SN - 2045-7634

IS - 1

ER -